28 May Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer
Promising preclinical data support continued development of novel receptor-based targeting molecule, ART-101, for the treatment of prostate cancer
Archeus plans to initiate Phase 1 trial with ART-101 in 2025
Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin–Madison (UW), today announced a strategic collaboration to advance ART-101 – a promising receptor-based targeting molecule – into clinical development.
ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW–Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by robust support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies, including significantly higher tumor uptake and retention relative to FDA-approved prostate cancer treatment Pluvicto® (177Lu-PSMA-617). It has also shown superior pharmacokinetics, dosimetry and normal tissue toxicity profiles.
Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care.